See more : Techpoint, Inc. (6697.T) Income Statement Analysis – Financial Results
Complete financial analysis of PharmaCielo Ltd. (PCLOF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PharmaCielo Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- UltraTech Cement Limited (UCLQF) Income Statement Analysis – Financial Results
- AnHui Wanyi Science and Technology Co., Ltd. (688600.SS) Income Statement Analysis – Financial Results
- Precipitate Gold Corp. (PREIF) Income Statement Analysis – Financial Results
- Park Hotels & Resorts Inc. (0KFU.L) Income Statement Analysis – Financial Results
- Lotte Tour Development Co., Ltd. (032350.KS) Income Statement Analysis – Financial Results
PharmaCielo Ltd. (PCLOF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.pharmacielo.com
About PharmaCielo Ltd.
PharmaCielo Ltd., together with its subsidiary, cultivates, processes, produces, and supplies medicinal-grade cannabis extracts, tetrahydrocannabinol, and related products. The company also offers telemedicine software. It serves health and wellness product manufacturers, pharmacies, medical clinics, and cosmetic companies in Canada and Colombia. The company has a strategic alliance with AssuredTrans Inc. PharmaCielo Ltd. is headquartered in Toronto, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.54M | 5.31M | 1.94M | 2.65M | 786.90K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.91M | 4.48M | 6.25M | 9.45M | 2.45M | 653.63K | 26.87K | 68.40K | 32.74K |
| Gross Profit | -1.37M | 827.06K | -4.31M | -6.80M | -1.66M | -653.63K | -26.87K | -68.40K | -32.74K |
| Gross Profit Ratio | -88.78% | 15.58% | -221.51% | -256.19% | -210.90% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 7.81M | 10.70M | 17.94M | 31.21M | 29.63M | 118.61K | 12.80M | 5.40M | 3.35M |
| Selling & Marketing | 411.96K | 779.19K | 1.08M | 1.13M | 900.66K | 1.31M | -12.79M | 1.16M | 737.91K |
| SG&A | 8.22M | 11.48M | 19.01M | 32.34M | 30.53M | 118.61K | 15.98K | 6.56M | 4.09M |
| Other Expenses | -9.59M | 873.13K | 136.63K | 949.03K | -218.73K | -25.79K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | -1.37M | 12.26M | 20.89M | 36.62M | 32.67M | 118.61K | 15.98K | 11.19M | 4.16M |
| Cost & Expenses | 11.24M | 16.74M | 27.14M | 46.07M | 35.12M | 118.61K | 15.98K | 11.26M | 4.20M |
| Interest Income | 176.00 | 1.83K | 2.37K | 65.58K | 585.13K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.86M | 1.54M | 561.29K | 272.73K | 173.84K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.41M | 1.58M | 1.32M | 1.48M | 1.28M | 653.63K | 806.55K | 32.83K | 5.61K |
| EBITDA | -12.19M | -9.88M | -24.84M | -41.92M | -32.68M | -30.98M | -15.98K | -6.65M | -4.12M |
| EBITDA Ratio | -790.59% | -186.12% | -1,244.64% | -1,565.79% | -4,153.31% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -9.70M | -11.46M | -25.46M | -43.12M | -33.96M | -118.61K | -15.98K | -6.69M | -4.12M |
| Operating Income Ratio | -629.22% | -215.87% | -1,309.24% | -1,624.81% | -4,316.11% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -6.60M | -3.08M | -1.44M | -634.62K | -703.86K | 31.44M | -16.36M | -4.58M | -71.45K |
| Income Before Tax | -16.30M | -14.52M | -26.63M | -43.76M | -34.67M | -144.40K | -15.98K | -11.26M | -4.20M |
| Income Before Tax Ratio | -1,057.09% | -273.45% | -1,369.14% | -1,648.73% | -4,405.55% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 1.57M | 288.00K | 504.42K | -44.88K | -161.14K | -806.55K | 216.34 | 0.00 |
| Net Income | -16.30M | -14.52M | -26.63M | -43.76M | -34.67M | -144.40K | -15.98K | -11.26M | -4.20M |
| Net Income Ratio | -1,057.09% | -273.45% | -1,369.14% | -1,648.73% | -4,405.55% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.10 | -0.10 | -0.18 | -0.39 | -0.36 | -1.18 | -0.04 | -0.22 | -0.18 |
| EPS Diluted | -0.10 | -0.10 | -0.18 | -0.39 | -0.36 | -1.18 | -0.04 | -0.22 | -0.18 |
| Weighted Avg Shares Out | 160.08M | 150.98M | 145.64M | 112.54M | 96.05M | 122.19K | 388.61K | 50.68M | 22.98M |
| Weighted Avg Shares Out (Dil) | 160.08M | 150.98M | 145.64M | 112.54M | 96.05M | 122.19K | 388.61K | 50.68M | 22.98M |
PharmaCielo Reports Q3 2024 Financial Results
PharmaCielo achieved 85% Year-Over-Year Sales Growth, Generating Year-to-Date Q3 Total Revenue of $2.4 Million Q3 Gross Profit Turned Positive Reflecting More Diverse Customer Base Q3 Cash Flow Improved and EBITDA Increased by $0.8 Million Reflecting Strong Sales Growth and Reduced...
PharmaCielo Announces Intention to Extend Expiry Date of Warrants
All figures in Canadian dollars ($) unless otherwise specified Toronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - November 5, 2024) - PharmaCielo Ltd. (TSXV: PCLO) (OTC: PCLOF) ("PharmaCielo" or the "Company"), the Canadian parent of Colombia's premier cultivator and producer of...
PharmaCielo Announces Change to Financial Year-End, and Appointment of Davidson & Company LLP as Auditor Effective October 7, 2024
All figures in Canadian dollars ($) unless otherwise specified Toronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - October 7, 2024) - PharmaCielo Ltd. (TSXV: PCLO) (OTC Pink: PCLOF) ("PharmaCielo" or the "Company"), the Canadian parent of Colombia's premier cultivator and producer...
PharmaCielo Announces Financial Results for the Second Quarter Ended June 30, 2024
All figures in Canadian dollars ($) unless otherwise specified Toronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - August 16, 2024) - PharmaCielo Ltd. (TSXV: PCLO) (OTC Pink: PCLOF) ("PharmaCielo" or the "Company"), the Canadian parent of Colombia's premier cultivator and producer...
CORRECTION FROM SOURCE: PharmaCielo Provides Update on Reinstatement for Trading
Toronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - July 17, 2024) - PharmaCielo Ltd. (TSXV: PCLO) (OTC Pink: PCLOF) ("PharmaCielo" or the "Company"), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia...
PharmaCielo Provides Update on Reinstatement for Trading
Toronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - July 17, 2024) - PharmaCielo Ltd. (TSXV: PCLO) (OTC Pink: PCLOF) ("PharmaCielo" or the "Company"), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia...
PharmaCielo Announces Financial Results for the Fourth Quarter and Fiscal Year Ended December 31, 2023, and the First Quarter Ended March 31, 2024
All figures in Canadian dollars ($) unless otherwise specified Toronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - July 4, 2024) - PharmaCielo Ltd. (TSXV: PCLO) (OTC Pink: PCLOF) ("PharmaCielo" or the "Company"), the Canadian parent of Colombia's premier cultivator and producer of...
PharmaCielo Announces Issuance of Failure to File Cease Trade Order
All amounts expressed in Canadian dollars unless otherwise noted Toronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - May 8, 2024) - PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF) ("PharmaCielo" or the "Company"), the Canadian parent of Colombia's premier cultivator and producer of...
PharmaCielo Signs Binding Letter of Intent to Acquire Operations in Thailand; Announces $2 Million Non-Brokered Private Placement with Participation from PharmaCielo Insiders and Siam Ventures Investors
The proposed acquisition of Siam Ventures, which provides contract manufacturing services through a subsidiary, will act as a gateway to large Asian markets for PharmaCielo product. Experienced investor, businessman and lawyer Louis Desmarais, the current Chairman and CEO of Siam...
PharmaCielo to Supply Ease Labs with Commercial Shipments of API to Fulfill Contract with State Government of Sao Paulo, Brazil
The contract to supply the State of São Paulo is the largest public sector contract awarded to date in Brazil - the State of São Paulo is the largest state in the country. Ease Labs to supply up to 1.871...
Source: https://incomestatements.info
Category: Stock Reports